New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...

New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...

Praxis Precision Medicines' ulixacaltamide (PRAX-944) is a potent and selective small molecule T-type Ca2+ channel blocker being developed for the potential treatment of essential tremor. ET is a ...

Myotonic dystrophy is one of the most common forms of muscular dystrophy. It is a genetic condition that causes progressive muscle weakness and wasting. No treatments currently exist that slow the ...

NEW YORK, July 31 (Praxis Press) Cardiovascular outcomes have not been compared in hypertensive patients treated with calcium channel blockers and in patients treated with older drugs. Hansson and ...

Findings provide reassurance to physicians and patients about the long-term safety of dihydropyridine calcium channel blockers in the treatment of pancreatic cancer. This was a new user, active ...

A new retrospective analysis of data from over 400,000 UK Biobank participants has revealed that calcium channel blockers (CCBs), but not other antihypertensive agents, were associated with an ...

A woman with hopes to conceive was diagnosed with severe vasospastic angina (VSA); however, she was able to carry a healthy baby to full term without angina attacks after starting treatment of a ...

Use of calcium channel blockers (CCBs), particularly cardioselective agents, had a modest but statistically significant association with glaucoma, a large meta-analysis showed. Overall, patients with ...

New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...